Market Research Logo

Atopic Dermatitis - Pipeline Review, H2 2015

Atopic Dermatitis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Atopic Dermatitis - Pipeline Review, H2 2015’, provides an overview of the Atopic Dermatitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Atopic Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atopic Dermatitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Atopic Dermatitis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Atopic Dermatitis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Atopic Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Atopic Dermatitis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Atopic Dermatitis Overview
Therapeutics Development
Pipeline Products for Atopic Dermatitis - Overview
Pipeline Products for Atopic Dermatitis - Comparative Analysis
Atopic Dermatitis - Therapeutics under Development by Companies
Atopic Dermatitis - Therapeutics under Investigation by Universities/Institutes
Atopic Dermatitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Atopic Dermatitis - Products under Development by Companies
Atopic Dermatitis - Products under Investigation by Universities/Institutes
Atopic Dermatitis - Companies Involved in Therapeutics Development
Abeome Corporation
AlbireoPharma
Almirall, S.A.
Amgen Inc.
Amorepacific Corporation
Anacor Pharmaceuticals, Inc.
AnaMar AB
AnaptysBio, Inc.
AnGes MG, Inc.
Aquinox Pharmaceuticals Inc.
arGEN-X BV
Blueberry Therapeutics Ltd
Brickell Biotech, Inc.
Celgene Corporation
ChemoCentryx, Inc.
ChironWells GmbH
Chugai Pharmaceutical Co., Ltd.
Creabilis SA
Delenex Therapeutics AG
Dermira Inc.
Dr. August Wolff GmbH & Co. KG Arzneimittle
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Foamix Pharmaceuticals Ltd.
Fountain Biopharma Inc.
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
Grupo Ferrer Internacional, S.A.
Han Wha Pharma Co., Ltd.
HanAll Biopharma Co., Ltd.
Herantis Pharma Plc
iCo Therapeutics Inc.
IMMD Inc.
Immune Pharmaceuticals Inc.
Inflamalps SA
Japan Tobacco Inc.
Johnson & Johnson
LegoChem Biosciences, Inc
LEO Pharma A/S
Madam Therapeutics B.V.
MedImmune, LLC
Mitsubishi Tanabe Pharma Corporation
NeoPharm Co., Ltd.
Novartis AG
Nuvo Research Inc.
Otsuka Holdings Co., Ltd.
Oxagen Limited
Pfizer Inc.
Pharis Biotec GmbH
Pharmedartis GmbH
Provectus Biopharmaceuticals, Inc.
R-Tech Ueno, Ltd.
Regeneron Pharmaceuticals, Inc.
Signum Dermalogix, Inc
Spherium Biomed S.L.
sterna biologicals Gmbh & Co KG
Sun Pharma Advanced Research Company Ltd.
SWITCH Biotech LLC
Takeda Pharmaceutical Company Limited
Thesan Pharmaceuticals, Inc.
Valeant Pharmaceuticals International, Inc.
Vicore Pharma AB
Vitae Pharmaceuticals, Inc.
VivaCell Biotechnology Espana S.L.
Welichem Biotech Inc.
Xencor, Inc.
Yungjin Pharm. Co., Ltd.
Ziarco Pharma Ltd
Atopic Dermatitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
A-3914 - Drug Profile
A-5425 - Drug Profile
AKP-11 - Drug Profile
ALX-101 - Drug Profile
AM-1030 - Drug Profile
AN-2898 - Drug Profile
AN-4161 - Drug Profile
ANB-020 - Drug Profile
apremilast - Drug Profile
Aptamers to Inhibit Galectin-3 for Atopic Dermatitis - Drug Profile
AQX-1125 - Drug Profile
ARGX-112 - Drug Profile
ARN-077 - Drug Profile
BB-2702 - Drug Profile
BBI-2111 - Drug Profile
BBI-5000 - Drug Profile
bertilimumab - Drug Profile
Biologic for Atopic Dermatitis and Eczema - Drug Profile
BPR-277 - Drug Profile
C-21 - Drug Profile
CBP-174 - Drug Profile
CBP-201 - Drug Profile
CCX-6239 - Drug Profile
CDE-001 - Drug Profile
Cis-Urocanic Acid - Drug Profile
CNTO-7160 - Drug Profile
cobamamide - Drug Profile
crisaborole - Drug Profile
CT-1x1 - Drug Profile
CT-1x2 - Drug Profile
CT-1x3 - Drug Profile
CT-327 - Drug Profile
CT-340 - Drug Profile
cyclosporine - Drug Profile
DRM-02 - Drug Profile
Drug for Atopic Dermatitis - Drug Profile
Drugs to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile
dupilumab - Drug Profile
E-6005 - Drug Profile
FB-825 - Drug Profile
fevipiprant - Drug Profile
FIB-116 - Drug Profile
Furestem-AD - Drug Profile
GBR-830 - Drug Profile
Histimex - Drug Profile
HS-378 - Drug Profile
IMD-0354 - Drug Profile
JTE-052 - Drug Profile
KTG-001 - Drug Profile
LCB-030110 - Drug Profile
lebrikizumab - Drug Profile
LEKTI-6 - Drug Profile
LEO-32731 - Drug Profile
LEO-39652 - Drug Profile
mepolizumab - Drug Profile
MLR-1130 - Drug Profile
mometasone furoate - Drug Profile
Monoclonal Antibodies to Inhibit IL-25 for Asthma, Fibrosis and Atopic Dermatitis - Drug Profile
Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis - Drug Profile
N-oleoylethanolamine - Drug Profile
nemolizumab - Drug Profile
NPB-3 - Drug Profile
NPH-12 - Drug Profile
OC-000459 - Drug Profile
OC-2417 - Drug Profile
octenidine hydrochloride - Drug Profile
OLX-103 - Drug Profile
omiganan pentahydrochloride - Drug Profile
OPA-15406 - Drug Profile
P-10 - Drug Profile
PAC-14028 - Drug Profile
PDI-192 - Drug Profile
Peptide to Antagonize CX3CR1 for Atopic Dermatitis - Drug Profile
Peptides to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile
PH-10 - Drug Profile
PL-601 - Drug Profile
PMA-101R - Drug Profile
PMA-201 - Drug Profile
PMA-411R - Drug Profile
Q-301 - Drug Profile
Qi-507 - Drug Profile
roflumilast - Drug Profile
RTU-1096 - Drug Profile
S-414114 - Drug Profile
SB-011 - Drug Profile
SIG-1311 - Drug Profile
SIG-1322 - Drug Profile
Small Molecule to Modulate S1PR1 for Atopic Dermatitis - Drug Profile
Small Molecules for Atopic Dermatitis - Drug Profile
Small Molecules to Inhibit Kinase for Inflammatory Diseases - Drug Profile
SP-14019 - Drug Profile
SUN-0597 - Drug Profile
SWT-01113 - Drug Profile
SWT-05141 - Drug Profile
Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile
TA-7906 - Drug Profile
tacrolimus - Drug Profile
tezepelumab - Drug Profile
tofacitinib - Drug Profile
tralokinumab - Drug Profile
ustekinumab - Drug Profile
VTP-38543 - Drug Profile
WBI-1001 - Drug Profile
WF-10 liposomal - Drug Profile
WOL-071007 - Drug Profile
XmAb-7195 - Drug Profile
YJC-10592 - Drug Profile
ZPL-3893787 - Drug Profile
ZPL-5212372 - Drug Profile
Atopic Dermatitis - Recent Pipeline Updates
Atopic Dermatitis - Dormant Projects
Atopic Dermatitis - Discontinued Products
Atopic Dermatitis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Atopic Dermatitis, H2 2015
Number of Products under Development for Atopic Dermatitis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Investigation by Universities/Institutes, H2 2015
Atopic Dermatitis - Pipeline by Abeome Corporation, H2 2015
Atopic Dermatitis - Pipeline by AlbireoPharma, H2 2015
Atopic Dermatitis - Pipeline by Almirall, S.A., H2 2015
Atopic Dermatitis - Pipeline by Amgen Inc., H2 2015
Atopic Dermatitis - Pipeline by Amorepacific Corporation, H2 2015
Atopic Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2015
Atopic Dermatitis - Pipeline by AnaMar AB, H2 2015
Atopic Dermatitis - Pipeline by AnaptysBio, Inc., H2 2015
Atopic Dermatitis - Pipeline by AnGes MG, Inc., H2 2015
Atopic Dermatitis - Pipeline by Aquinox Pharmaceuticals Inc., H2 2015
Atopic Dermatitis - Pipeline by arGEN-X BV, H2 2015
Atopic Dermatitis - Pipeline by Blueberry Therapeutics Ltd, H2 2015
Atopic Dermatitis - Pipeline by Brickell Biotech, Inc., H2 2015
Atopic Dermatitis - Pipeline by Celgene Corporation, H2 2015
Atopic Dermatitis - Pipeline by ChemoCentryx, Inc., H2 2015
Atopic Dermatitis - Pipeline by ChironWells GmbH, H2 2015
Atopic Dermatitis - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2015
Atopic Dermatitis - Pipeline by Creabilis SA, H2 2015
Atopic Dermatitis - Pipeline by Delenex Therapeutics AG, H2 2015
Atopic Dermatitis - Pipeline by Dermira Inc., H2 2015
Atopic Dermatitis - Pipeline by Dr. August Wolff GmbH & Co. KG Arzneimittle, H2 2015
Atopic Dermatitis - Pipeline by Eisai Co., Ltd., H2 2015
Atopic Dermatitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Atopic Dermatitis - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015
Atopic Dermatitis - Pipeline by Fountain Biopharma Inc., H2 2015
Atopic Dermatitis - Pipeline by GlaxoSmithKline Plc, H2 2015
Atopic Dermatitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2015
Atopic Dermatitis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2015
Atopic Dermatitis - Pipeline by Han Wha Pharma Co., Ltd., H2 2015
Atopic Dermatitis - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
Atopic Dermatitis - Pipeline by Herantis Pharma Plc, H2 2015
Atopic Dermatitis - Pipeline by iCo Therapeutics Inc., H2 2015
Atopic Dermatitis - Pipeline by IMMD Inc., H2 2015
Atopic Dermatitis - Pipeline by Immune Pharmaceuticals Inc., H2 2015
Atopic Dermatitis - Pipeline by Inflamalps SA, H2 2015
Atopic Dermatitis - Pipeline by Japan Tobacco Inc., H2 2015
Atopic Dermatitis - Pipeline by Johnson & Johnson, H2 2015
Atopic Dermatitis - Pipeline by LegoChem Biosciences, Inc, H2 2015
Atopic Dermatitis - Pipeline by LEO Pharma A/S, H2 2015
Atopic Dermatitis - Pipeline by Madam Therapeutics B.V., H2 2015
Atopic Dermatitis - Pipeline by MedImmune, LLC, H2 2015
Atopic Dermatitis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015
Atopic Dermatitis - Pipeline by NeoPharm Co., Ltd., H2 2015
Atopic Dermatitis - Pipeline by Novartis AG, H2 2015
Atopic Dermatitis - Pipeline by Nuvo Research Inc., H2 2015
Atopic Dermatitis - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
Atopic Dermatitis - Pipeline by Oxagen Limited, H2 2015
Atopic Dermatitis - Pipeline by Pfizer Inc., H2 2015
Atopic Dermatitis - Pipeline by Pharis Biotec GmbH, H2 2015
Atopic Dermatitis - Pipeline by Pharmedartis GmbH, H2 2015
Atopic Dermatitis - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2015
Atopic Dermatitis - Pipeline by R-Tech Ueno, Ltd., H2 2015
Atopic Dermatitis - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015
Atopic Dermatitis - Pipeline by Signum Dermalogix, Inc, H2 2015
Atopic Dermatitis - Pipeline by Spherium Biomed S.L., H2 2015
Atopic Dermatitis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2015
Atopic Dermatitis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015
Atopic Dermatitis - Pipeline by SWITCH Biotech LLC, H2 2015
Atopic Dermatitis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Atopic Dermatitis - Pipeline by Thesan Pharmaceuticals, Inc., H2 2015
Atopic Dermatitis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2015
Atopic Dermatitis - Pipeline by Vicore Pharma AB, H2 2015
Atopic Dermatitis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2015
Atopic Dermatitis - Pipeline by VivaCell Biotechnology Espana S.L., H2 2015
Atopic Dermatitis - Pipeline by Welichem Biotech Inc., H2 2015
Atopic Dermatitis - Pipeline by Xencor, Inc., H2 2015
Atopic Dermatitis - Pipeline by Yungjin Pharm. Co., Ltd., H2 2015
Atopic Dermatitis - Pipeline by Ziarco Pharma Ltd, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Atopic Dermatitis Therapeutics - Recent Pipeline Updates, H2 2015
Atopic Dermatitis - Dormant Projects, H2 2015
Atopic Dermatitis - Dormant Projects (Contd..1), H2 2015
Atopic Dermatitis - Dormant Projects (Contd..2), H2 2015
Atopic Dermatitis - Dormant Projects (Contd..3), H2 2015
Atopic Dermatitis - Dormant Projects (Contd..4), H2 2015
Atopic Dermatitis - Dormant Projects (Contd..5), H2 2015
Atopic Dermatitis - Dormant Projects (Contd..6), H2 2015
Atopic Dermatitis - Dormant Projects (Contd..7), H2 2015
Atopic Dermatitis - Dormant Projects (Contd..8), H2 2015
Atopic Dermatitis - Discontinued Products, H2 2015
Atopic Dermatitis - Discontinued Products (Contd..1), H2 2015
List of Figures
Number of Products under Development for Atopic Dermatitis, H2 2015
Number of Products under Development for Atopic Dermatitis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report